Healio (5/16, Downey) reports, “Intravenous [IV] ketamine and intranasal esketamine were shown to improve symptoms of depression among adults,” researchers concluded in a 210-patient analysis in which “126 (61.4%) received IV ketamine, and 81 received intranasal esketamine.”  Psychiatric News (5/16) reports, “Intravenous ketamine may improve patients’ depressive symptoms more rapidly than intranasal esketamine,” the study revealed. The findings were published online May 11 in a research letter in JAMA Psychiatry.  (SOURCE: APA Headlines)